GoKawiilIn vivo CAR-T therapy shows early promise for multiple sclerosis in small trial
A phase of clinical testing involving sixteen patients with multiple sclerosis and related autoimmune disorders showed symptom improvement after researchers used a modified virus to instruct T cells inside the body to produce chimeric antigen receptors, targeting the B cells responsible for autoimmune attacks. The findings, published this week in The New England Journal of Medicine, mark one of the first demonstrations that CAR-T therapy can be generated directly inside a patient rather than engineered in a lab and reinfused.